Replimune Group (NASDAQ:REPL) Announces Earnings Results

Replimune Group (NASDAQ:REPL) released its earnings results on Monday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10), FiscalAI reports.

Replimune Group Trading Down 1.2%

Shares of NASDAQ REPL opened at $11.07 on Wednesday. The stock has a market capitalization of $914.05 million, a P/E ratio of -3.28 and a beta of 0.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The business’s 50 day moving average is $6.59 and its two-hundred day moving average is $7.30. Replimune Group has a 1-year low of $1.50 and a 1-year high of $13.24.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price target on the stock in a research note on Friday, June 26th. Wedbush lifted their target price on Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a report on Tuesday. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.12.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Replimune Group by 17.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after purchasing an additional 6,653 shares during the last quarter. Millennium Management LLC boosted its position in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after buying an additional 33,574 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. Rhumbline Advisers raised its stake in shares of Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.